TriangleNCT02557035 · CITED IN SOURCE DOCUMENTS
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2018-06-20
PALO-15-17 is a clinical study assessing efficacy and safety of a single dose of palonosetron 0.25 mg administered as a 30-minute IV infusion compared to palonosetron 0.25 mg administered as a 30-second IV bolus (Aloxi, an antiemetic drug), both given with oral dexamethasone. The objective of the study is to demonstrate that infused IV palonosetron 0.25 mg is as effective as (non-inferior to) injected palonosetron IV 0.25 mg to prevent nausea and vomiting induced by highly emetogenic cancer chemotherapy in the 0-24 hours after administration of a single cycle of highly emetogenic chemotherapy
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Acute Phase
Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Delayed Phase
Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Overall Phase
Percentage of Patients With no Emetic Episodes in the Acute Phase
Percentage of Patients With no Emetic Episodes in the Delayed Phase
Percentage of Patients With no Emetic Episodes in the Overall Phase
Percentage of Patients With no Rescue Medication in the Acute Phase
Percentage of Patients With no Rescue Medication in the Delayed Phase
Percentage of Patients With no Rescue Medication in the Overall Phase
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Signed written informed consent * Histologically or cytologically confirmed solid tumor malignancy. * Naïve to cytotoxic chemotherapy. Previous biological or hormonal therapy will be permitted. * Scheduled to receive first course of one of the following reference HEC, alone or in combination with other chemotherapeutic agents on Day 1: * cisplatin administered as a single IV dose of ≥ 70 mg/m2 * cyclophosphamide ≥1500 mg/m2 * carmustine (BCNU) \>250 mg/m2 * dacarbazine (DTIC) * mechloretamine (nitrogen mustard) * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 . * If a patient is female, she shall be of non-childbearing potential or of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test. * Hematologic and metabolic status adequate for receiving an highly emetogenic regimen based on laboratory criteria (Total Neutrophils,Platelets, Bilirubin, Liver enzymes, Serum Creatinine or Creatinine Clearance) * Able to read, understand, follow the study procedure and complete patient diary. Exclusion Criteria: * Lactating woman. * Current use of illicit drugs or current evidence of alcohol abuse. * Scheduled to receive moderately emetogenic chemotherapy or highly emetogenic chemotherapy from Day 2 to Day 5. * Received or is scheduled to receive radiation therapy to the abdomen or the pelvis within 1 week prior to the start of the reference HEC administration on Day 1 or between Days 1 to 5. * Any vomiting, retching, or nausea (grade ≥ 1 as defined by National Cancer Institute) within 24 hours prior to the start of the reference HEC administration on Day 1. * Symptomatic primary or metastatic CNS malignancy. * Active peptic ulcer disease, gastrointestinal obstruction, increased intracranial pressure, hypercalcemia, an active infection or any illness or medical conditions (other than malignancy) that, in the opinion of the Investigator, may confound the results of the study, represent another potential etiology for emesis and nausea (other than chemotherapy-induced nausea and vomiting) or pose unwarranted risks in administering the study drugs to the patient. * Known hypersensitivity or contraindication to 5-HT3 receptor antagonists * Known contraindication to the IV administration of 50 mL 5% glucose solution. * Participation in a previous clinical trial involving palonosetron. * Any investigational drugs (other than those given in this study) taken within 4 weeks prior to Day 1, and/or is scheduled to receive any investigational drug during the present study. * Systemic corticosteroid therapy at any dose within 72 hours prior to the start of the reference HEC administration on Day 1. However, topical and inhaled corticosteroids are permitted. * Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy. * Any medication with known or potential antiemetic activity within 24 hours prior to the start of the reference HEC administration on Day 1, including but not limited to 5-HT3 receptor antagonists and NK-1 receptor antagonists * Concurrent medical condition that would preclude administration of dexamethasone for 4 days such as systemic fungal infection or uncontrolled diabetes.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
- intervention Names
- Drug: Palonosetron
- Drug: Dexamethasone
- label
- I.V. palonosetron infusion plus dexamethasone
- type
- EXPERIMENTAL
- description
- Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
- intervention Names
- Drug: Palonosetron
- Drug: Dexamethasone
- label
- I.V. palonosetron bolus plus dexamethasone
- type
- ACTIVE_COMPARATOR
- interventions
- arm Group Labels
- I.V. palonosetron bolus plus dexamethasone
- I.V. palonosetron infusion plus dexamethasone
- name
- Palonosetron
- type
- DRUG
- arm Group Labels
- I.V. palonosetron bolus plus dexamethasone
- I.V. palonosetron infusion plus dexamethasone
- name
- Dexamethasone
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- QUADRUPLE
- who Masked
- PARTICIPANT
- CARE_PROVIDER
- INVESTIGATOR
- OUTCOMES_ASSESSOR
- primary Purpose
- PREVENTION
Enrollment
- count
- 441
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- measure
- Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Acute Phase
- time Frame
- 0-24 hours
- secondary Outcomes
- measure
- Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Delayed Phase
- time Frame
- >24-120 hours
- measure
- Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Overall Phase
- time Frame
- 0-120 hours
- measure
- Percentage of Patients With no Emetic Episodes in the Acute Phase
- time Frame
- 0-24 hours
- measure
- Percentage of Patients With no Emetic Episodes in the Delayed Phase
- time Frame
- >24-120 hours
- measure
- Percentage of Patients With no Emetic Episodes in the Overall Phase
- time Frame
- 0-120 hours
- measure
- Percentage of Patients With no Rescue Medication in the Acute Phase
- time Frame
- 0-24 hours
- measure
- Percentage of Patients With no Rescue Medication in the Delayed Phase
- time Frame
- >24-120 hours
- measure
- Percentage of Patients With no Rescue Medication in the Overall Phase
- time Frame
- 0-120 hours
Full study description
- brief Summary
- PALO-15-17 is a clinical study assessing efficacy and safety of a single dose of palonosetron 0.25 mg administered as a 30-minute IV infusion compared to palonosetron 0.25 mg administered as a 30-second IV bolus (Aloxi, an antiemetic drug), both given with oral dexamethasone. The objective of the study is to demonstrate that infused IV palonosetron 0.25 mg is as effective as (non-inferior to) injected palonosetron IV 0.25 mg to prevent nausea and vomiting induced by highly emetogenic cancer chemotherapy in the 0-24 hours after administration of a single cycle of highly emetogenic chemotherapy
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-b5680880c52711e6066e
- requested nct id
- NCT02557035
- primary nct id
- NCT02557035
- source kind
- fda_spl_label
- source record id
- c1a46993-d1bf-4f84-8fac-e9c04a7d6bf1
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- 86cec1463316cb80111fd54defc77b2af951504615cad6975860d92748e271d4
- payload
- application numbers
- NDA205718
- NDA210493
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-b5680880c52711e6066e
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02557035
- occurrences
- context exact
- CI for the difference in proportions of patients with CR was greater (i.e., closer to zero) than the pre‑defined non‑inferiority margin set at ‑15%. Study 5 ( NCT02557035 ) In a multicenter, multinational, randomized, active controlled, double blind, double dummy, parallel group, clinical non-inferiority study, the efficacy and
- end
- 7810
- exact text
- NCT02557035
- start
- 7799
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/48/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- c1a46993-d1bf-4f84-8fac-e9c04a7d6bf1
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 40fb980a67afbc7b246cf52fd3b76f1ee849d8f5e1441e858a9615c872996105
- spl effective time
- 20260623
- spl set id
- 8e47618e-af46-4d82-94e8-1507c042252d
Preserved source evidence · Not medical advice